Nothing Special   »   [go: up one dir, main page]

DE60133897D1 - Substituierte chinazolin-derivate und deren verwendung als aurora-2-kinase inhibitoren - Google Patents

Substituierte chinazolin-derivate und deren verwendung als aurora-2-kinase inhibitoren

Info

Publication number
DE60133897D1
DE60133897D1 DE60133897T DE60133897T DE60133897D1 DE 60133897 D1 DE60133897 D1 DE 60133897D1 DE 60133897 T DE60133897 T DE 60133897T DE 60133897 T DE60133897 T DE 60133897T DE 60133897 D1 DE60133897 D1 DE 60133897D1
Authority
DE
Germany
Prior art keywords
chinazolin
aurora
derivatives
substituted
kinase inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60133897T
Other languages
English (en)
Inventor
Andrew Mortlock
Frederic Jung
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Application granted granted Critical
Publication of DE60133897D1 publication Critical patent/DE60133897D1/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DE60133897T 2000-06-28 2001-06-21 Substituierte chinazolin-derivate und deren verwendung als aurora-2-kinase inhibitoren Expired - Fee Related DE60133897D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00401842 2000-06-28
PCT/SE2001/001450 WO2002000649A1 (en) 2000-06-28 2001-06-21 Substituted quinazoline derivatives and their use as inhibitors

Publications (1)

Publication Number Publication Date
DE60133897D1 true DE60133897D1 (de) 2008-06-19

Family

ID=8173742

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60133897T Expired - Fee Related DE60133897D1 (de) 2000-06-28 2001-06-21 Substituierte chinazolin-derivate und deren verwendung als aurora-2-kinase inhibitoren

Country Status (27)

Country Link
US (2) US6919338B2 (de)
EP (1) EP1299381B1 (de)
JP (1) JP2004501914A (de)
KR (1) KR20030014411A (de)
CN (1) CN1267431C (de)
AR (1) AR030432A1 (de)
AT (1) ATE394102T1 (de)
AU (1) AU2001266505A1 (de)
BG (1) BG107376A (de)
BR (1) BR0111754A (de)
CA (1) CA2412592A1 (de)
CZ (1) CZ20024120A3 (de)
DE (1) DE60133897D1 (de)
EE (1) EE200200715A (de)
ES (1) ES2305081T3 (de)
HK (1) HK1053124A1 (de)
HU (1) HUP0301236A2 (de)
IL (1) IL153246A0 (de)
IS (1) IS6656A (de)
MX (1) MXPA02011974A (de)
NO (1) NO20026010L (de)
NZ (1) NZ522696A (de)
PL (1) PL360439A1 (de)
RU (1) RU2283311C2 (de)
SK (1) SK18102002A3 (de)
WO (1) WO2002000649A1 (de)
ZA (1) ZA200209412B (de)

Families Citing this family (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0302172A2 (hu) 2000-09-15 2003-09-29 Vertex Pharmaceuticals Incorporated Protein kináz inhibitorokként alkalmazható pirazolvegyületek
US7473691B2 (en) * 2000-09-15 2009-01-06 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US6660731B2 (en) * 2000-09-15 2003-12-09 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
KR100909665B1 (ko) * 2000-12-21 2009-07-29 버텍스 파마슈티칼스 인코포레이티드 단백질 키나제 억제제로서 유용한 피라졸 화합물 및 이를 포함하는 약제학적 조성물
RU2323215C2 (ru) 2001-12-24 2008-04-27 Астразенека Аб Замещенные производные хиназолина как ингибиторы ауроракиназы
RU2004126671A (ru) * 2002-02-06 2005-04-10 Вертекс Фармасьютикалз Инкорпорейтед (Us) Гетероарилсоединения, полезные в качестве ингибиторов gsk-3
WO2003075921A2 (en) * 2002-03-05 2003-09-18 Transtech Pharma, Inc. Mono- and bicyclic azole derivatives that inhibit the interaction of ligands with rage
AU2003218215A1 (en) * 2002-03-15 2003-09-29 Vertex Pharmaceuticals, Inc. Azolylaminoazines as inhibitors of protein kinases
ATE489384T1 (de) * 2002-05-06 2010-12-15 Vertex Pharma Thiadiazole oder oxadiazole und ihre verwendung als jak proteinkinaseinhibitoren
MY141867A (en) * 2002-06-20 2010-07-16 Vertex Pharma Substituted pyrimidines useful as protein kinase inhibitors
ES2400339T3 (es) 2002-07-15 2013-04-09 Symphony Evolution, Inc. Compuestos, composiciones farmacéuticas de los mismos y su uso en el tratamiento del cáncer
EP1532145B1 (de) 2002-08-02 2006-09-13 Vertex Pharmaceuticals Incorporated Pyrazolenthaltende zusammensetzungen und ihre verwendung als gsk-3 inhibitoren
GB0221245D0 (en) * 2002-09-13 2002-10-23 Astrazeneca Ab Chemical process
WO2004058781A1 (en) 2002-12-24 2004-07-15 Astrazeneca Ab Phosphonooxy quinazoline derivatives and their pharmaceutical use
CN101074227B (zh) * 2002-12-24 2010-09-29 阿斯利康(瑞典)有限公司 膦酰氧基喹唑啉衍生物及其药物用途
EP1575946A1 (de) * 2002-12-24 2005-09-21 AstraZeneca AB Chinazoline verbindungen
US7601718B2 (en) * 2003-02-06 2009-10-13 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of protein kinases
EP1613619B1 (de) * 2003-04-16 2008-03-26 AstraZeneca AB Quinazolin-derivate für die behandling von krebs
EP1635823A1 (de) * 2003-05-20 2006-03-22 TransTech Pharma Inc. Rage antagonisten in der behandlung amyloidosis und anderer assoziierten krankheiten
WO2004105764A1 (en) * 2003-06-02 2004-12-09 Astrazeneca Ab (3- ((quinazolin-4-yl) amino )-1h-pyrazol-1-yl) acetamide derivatives and related compounds as aurora kinase inhibitors for the treatment of proliferative diseases such as cancer
TW200505452A (en) * 2003-06-17 2005-02-16 Astrazeneca Ab Chemical compounds
GB0320793D0 (en) * 2003-09-05 2003-10-08 Astrazeneca Ab Chemical process
SI2213661T1 (sl) 2003-09-26 2011-11-30 Exelixis Inc c-Met modulatorji in postopki uporabe
US20080051414A1 (en) * 2003-10-14 2008-02-28 Arizona Board Of Regents On Behalf Of The University Of Arizona Protein Kinase Inhibitors
US20090143399A1 (en) * 2003-10-14 2009-06-04 Arizona Board Of Regents On Behalf Of The University Of Arizona Protein Kinase Inhibitors
US20090099165A1 (en) * 2003-10-14 2009-04-16 Arizona Board Of Regents On Behalf Of The University Of Arizona Protein Kinase Inhibitors
DE602004022318D1 (de) * 2003-10-14 2009-09-10 Supergen Inc Proteinkinaseinhibitoren
EP1678149A2 (de) * 2003-10-31 2006-07-12 Neurogen Corporation 4-amino(aza)chinolinderivate als capsaicinrezeptoragonisten
CN1902193B (zh) * 2003-12-04 2011-07-13 沃泰克斯药物股份有限公司 可用作蛋白激酶抑制剂的喹喔啉
WO2005061519A1 (en) * 2003-12-19 2005-07-07 Takeda San Diego, Inc. Kinase inhibitors
US8119684B2 (en) * 2003-12-30 2012-02-21 Dana-Farber Cancer Institute, Inc. Thiophene derivatives for up-regulating HLA-DM activity
US7687502B2 (en) * 2004-03-23 2010-03-30 Banyu Pharmaceutical Co., Ltd. Substituted quinazoline or pyridopyrimidine derivative
JP2007533753A (ja) * 2004-04-23 2007-11-22 タケダ サン ディエゴ インコーポレイテッド インドール誘導体及びキナーゼ阻害剤としてのその使用
WO2006023931A2 (en) * 2004-08-18 2006-03-02 Takeda San Diego, Inc. Kinase inhibitors
WO2006040520A1 (en) 2004-10-12 2006-04-20 Astrazeneca Ab Quinazoline derivatives
US20090036485A1 (en) * 2004-10-12 2009-02-05 Frederic Henri Jung Quinoline derivatives
ATE479687T1 (de) 2004-10-15 2010-09-15 Takeda Pharmaceutical Kinaseinhibitoren
CN1854130B (zh) * 2005-04-15 2011-04-20 中国医学科学院药物研究所 喹唑啉衍生物、及其制法和药物组合物与用途
GB0509227D0 (en) * 2005-05-05 2005-06-15 Chroma Therapeutics Ltd Intracellular enzyme inhibitors
GB0510963D0 (en) * 2005-05-28 2005-07-06 Astrazeneca Ab Chemical compounds
JP2009504771A (ja) * 2005-08-18 2009-02-05 バーテックス ファーマシューティカルズ インコーポレイテッド ピラジンキナーゼ阻害剤
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
AU2006311830B2 (en) * 2005-11-03 2013-03-14 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as kinase inhibitors
EP1785420A1 (de) * 2005-11-14 2007-05-16 4Sc Ag Thiazolanalogen und ihre Verwendung
AU2007208351C1 (en) 2006-01-23 2011-07-07 Amgen Inc. Aurora kinase modulators and method of use
US7560551B2 (en) * 2006-01-23 2009-07-14 Amgen Inc. Aurora kinase modulators and method of use
US7868177B2 (en) * 2006-02-24 2011-01-11 Amgen Inc. Multi-cyclic compounds and method of use
WO2007099323A2 (en) * 2006-03-02 2007-09-07 Astrazeneca Ab Quinoline derivatives
UY30183A1 (es) 2006-03-02 2007-10-31 Astrazeneca Ab Derivados de quinolina
WO2007113005A2 (en) * 2006-04-03 2007-10-11 European Molecular Biology Laboratory (Embl) 2-substituted 3-aminosulfonyl-thiophene derivatives as aurora kinase inhibitors
MX2009003793A (es) 2006-10-09 2009-12-14 Takeda Pharmaceutical Inhibidores de cinasa.
JP5528806B2 (ja) 2006-10-12 2014-06-25 アステックス、セラピューティックス、リミテッド 複合薬剤
US8883790B2 (en) 2006-10-12 2014-11-11 Astex Therapeutics Limited Pharmaceutical combinations
US8236823B2 (en) * 2006-10-27 2012-08-07 Amgen Inc. Multi-cyclic compounds and methods of use
US20080207632A1 (en) * 2006-10-31 2008-08-28 Supergen, Inc. Protein kinase inhibitors
CA2668429A1 (en) * 2006-11-02 2008-05-15 Vertex Pharmaceuticals Incorporated Aminopyridines and aminopyrimidines useful as inhibitors of protein kinases
WO2008077086A1 (en) * 2006-12-19 2008-06-26 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as inhibitors of protein kinases
CA2680029A1 (en) * 2007-03-09 2008-09-18 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as inhibitors of protein kinases
CA2679701A1 (en) 2007-03-09 2008-09-18 Vertex Pharmaceuticals Incorporated Aminopyridines useful as inhibitors of protein kinases
CA2679884A1 (en) * 2007-03-09 2008-09-18 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as inhibitors of protein kinases
MX2009010517A (es) 2007-04-05 2009-10-19 Amgen Inc Moduladores de cinasa aurora y metodos de uso.
WO2008128009A2 (en) 2007-04-13 2008-10-23 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as kinase inhibitors
JP5572087B2 (ja) * 2007-05-02 2014-08-13 バーテックス ファーマシューティカルズ インコーポレイテッド キナーゼ阻害として有用なアミノピリミジン
JP5389786B2 (ja) * 2007-05-02 2014-01-15 バーテックス ファーマシューティカルズ インコーポレイテッド キナーゼ阻害として有用なアミノピリミジン
WO2008137619A2 (en) 2007-05-02 2008-11-13 Vertex Pharmaceuticals Incorporated Thiazoles and pyrazoles useful as kinase inhibitors
GB0709031D0 (en) 2007-05-10 2007-06-20 Sareum Ltd Pharmaceutical compounds
AU2008257044A1 (en) * 2007-05-24 2008-12-04 Vertex Pharmaceuticals Incorporated Thiazoles and pyrazoles useful as kinase inhibitors
ES2395581T3 (es) * 2007-06-20 2013-02-13 Merck Sharp & Dohme Corp. Inhibidores de quinasas janus
EP2170842A1 (de) * 2007-06-21 2010-04-07 Irm, Llc Proteinkinasehemmer und ihre anwendungsverfahren
EP2176261B1 (de) * 2007-07-31 2012-12-19 Vertex Pharmaceuticals Incorporated Verfahren für die zubereitung von 5-fluor-1h-pyrazolo [3, 4-b] pyridin-3-amin und derivaten davon
DE102008015032A1 (de) 2008-03-17 2009-09-24 Aicuris Gmbh & Co. Kg Substituierte Pyrazolamide und ihre Verwendung
DE102008015033A1 (de) 2008-03-17 2009-09-24 Aicuris Gmbh & Co. Kg Substituierte (Pyrazolyl-carbonyl)imidazolidinone und ihre Verwendung
US8404694B2 (en) * 2008-03-20 2013-03-26 Amgen Inc. Aurora kinase modulators and method of use
WO2010019473A1 (en) 2008-08-14 2010-02-18 Amgen Inc. Aurora kinase modulators and methods of use
EP2323622A1 (de) * 2008-09-03 2011-05-25 Vertex Pharmaceuticals Incorporated Co-kristalle und diese enthaltende pharmazeutische formulierungen
GB0820819D0 (en) 2008-11-13 2008-12-24 Sareum Ltd Pharmaceutical compounds
ES2489040T3 (es) 2008-12-03 2014-09-01 The Scripps Research Institute Cultivos de células madre
DE102008062878A1 (de) 2008-12-17 2010-06-24 Aicuris Gmbh & Co. Kg Substituierte Furancarboxamide und ihre Verwendung
DE102008062863A1 (de) 2008-12-17 2010-06-24 Aicuris Gmbh & Co. Kg Substituierte (Thiophenyl-carbonyl)imidazolidinone und ihre Verwendung
AU2010204619B2 (en) 2009-01-16 2016-08-11 Exelixis, Inc. Malate salt of N-(4-{ [ 6, 7-bis (methyloxy)-quinolin-4-yl] oxy}phenyl)-N'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer
BRPI1008325A2 (pt) * 2009-02-11 2020-08-25 Merck Patent Gmbh carboxamidas azaeterocíclicas de amino
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
ES2467923T3 (es) 2009-09-30 2014-06-13 Transtech Pharma, Llc Derivados de imidazol substituidos para el tratamiento de la enfermedad de Alzheimer
JP2013523894A (ja) 2010-04-14 2013-06-17 ブリストル−マイヤーズ スクイブ カンパニー 新規グルコキナーゼアクチベーターおよびその使用方法
US9090633B2 (en) 2010-11-18 2015-07-28 Kasina Laila Innova Pharmaceuticals Private Limited Substituted 4-(arylamino) selenophenopyrimidine compounds and methods of use thereof
WO2012066578A2 (en) * 2010-11-18 2012-05-24 Kasina Laila Innova Pharmaceuticals Private Limited Substituted 4-(selenophen-2(or 3)-ylamino)pyrimidine compounds and methods of use thereof
US8785459B2 (en) * 2011-12-27 2014-07-22 Development Center For Biotechnology Quinazoline compounds as kinase inhibitors
GB201202027D0 (en) 2012-02-06 2012-03-21 Sareum Ltd Pharmaceutical compounds
PL2634185T3 (pl) 2012-03-02 2016-06-30 Sareum Ltd Inhibitory kinazy TYK2
CN103788085B (zh) * 2012-10-31 2016-09-07 复旦大学 2-（喹唑啉-4-氨基）-5-噻唑甲酰胺类衍生物及其生物药物用途
CN104098551B (zh) * 2013-04-03 2019-03-22 广东东阳光药业有限公司 作为欧若拉激酶抑制剂的取代喹唑啉类衍生物
CN105555315B (zh) 2013-09-16 2019-05-07 阿斯利康(瑞典)有限公司 治疗性聚合物纳米颗粒及其制备和使用方法
CN108473435A (zh) 2015-10-05 2018-08-31 纽约市哥伦比亚大学理事会 自噬潮和磷脂酶d的活化剂以及包括tau的蛋白聚集体的清除和蛋白质病的治疗
GB201617871D0 (en) 2016-10-21 2016-12-07 Sareum Limited Pharmaceutical compounds
AR112027A1 (es) * 2017-06-15 2019-09-11 Biocryst Pharm Inc Inhibidores de alk 2 quinasa que contienen imidazol
EP4025565A1 (de) * 2019-09-06 2022-07-13 Inflazome Limited Nlrp3-inhibitoren
CN110746398A (zh) * 2019-10-18 2020-02-04 刘沛友 4-杂环取代喹唑啉类衍生物及其制备方法和用途
CN111574473A (zh) * 2020-06-04 2020-08-25 宁夏农林科学院农业资源与环境研究所（宁夏土壤与植物营养重点实验室） 一种氨基噻唑类化合物的合成方法
CN113311166B (zh) * 2021-04-28 2022-10-28 新疆农垦科学院 一种用于绵羊早期妊娠诊断的蛋白生物标志物及其用于绵羊早期妊娠检测的方法
CN115557601B (zh) * 2022-11-08 2024-11-08 成都理工大学 生物质微球及其制备方法与应用、生物反应器、地下井
WO2024184550A1 (en) * 2023-03-09 2024-09-12 Cancer Research Technology Limited Biarylamide derivatives and their use as pkmyt1 inhibitors

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3870725A (en) * 1971-03-30 1975-03-11 Lilly Industries Ltd Nitrothiazole derivatives
US5710158A (en) 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
AU658646B2 (en) 1991-05-10 1995-04-27 Rhone-Poulenc Rorer International (Holdings) Inc. Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
NZ243082A (en) * 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
IL117620A0 (en) * 1995-03-27 1996-07-23 Fujisawa Pharmaceutical Co Heterocyclic compounds processes for the preparation thereof and pharmaceutical compositions containing the same
GB9514265D0 (en) * 1995-07-13 1995-09-13 Wellcome Found Hetrocyclic compounds
US6716575B2 (en) * 1995-12-18 2004-04-06 Sugen, Inc. Diagnosis and treatment of AUR1 and/or AUR2 related disorders
TW436485B (en) * 1997-08-01 2001-05-28 American Cyanamid Co Substituted quinazoline derivatives
GB9800569D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
GB9800575D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
ES2241324T3 (es) * 1998-10-08 2005-10-16 Astrazeneca Ab Derivados de quinazolina.
GB9922171D0 (en) * 1999-09-21 1999-11-17 Zeneca Ltd Chemical compounds

Also Published As

Publication number Publication date
US20060046987A1 (en) 2006-03-02
ZA200209412B (en) 2004-02-19
CA2412592A1 (en) 2002-01-03
KR20030014411A (ko) 2003-02-17
CN1267431C (zh) 2006-08-02
HK1053124A1 (en) 2003-10-10
PL360439A1 (en) 2004-09-06
RU2283311C2 (ru) 2006-09-10
CZ20024120A3 (cs) 2003-03-12
BR0111754A (pt) 2003-04-29
NO20026010D0 (no) 2002-12-13
MXPA02011974A (es) 2004-09-06
EP1299381A1 (de) 2003-04-09
BG107376A (bg) 2003-09-30
ES2305081T3 (es) 2008-11-01
WO2002000649A9 (en) 2007-09-20
IS6656A (is) 2002-12-17
NO20026010L (no) 2002-12-13
ATE394102T1 (de) 2008-05-15
EP1299381B1 (de) 2008-05-07
SK18102002A3 (sk) 2003-07-01
AR030432A1 (es) 2003-08-20
AU2001266505A1 (en) 2002-01-08
IL153246A0 (en) 2003-07-06
CN1496364A (zh) 2004-05-12
WO2002000649A1 (en) 2002-01-03
JP2004501914A (ja) 2004-01-22
EE200200715A (et) 2004-08-16
HUP0301236A2 (hu) 2003-10-28
NZ522696A (en) 2004-08-27
US6919338B2 (en) 2005-07-19
US20030187002A1 (en) 2003-10-02

Similar Documents

Publication Publication Date Title
DE60133897D1 (de) Substituierte chinazolin-derivate und deren verwendung als aurora-2-kinase inhibitoren
DE60113719D1 (de) Chinuclidincarbamat derivate und deren verwendung als m3 antagonisten
ATE461171T1 (de) Neue mandelsäurederivate und deren verwendung als thrombininhibitoren
DE60332023D1 (de) Chinolinderivate und deren verwendung als mycobakterielle inhibitoren
DE60221233D1 (de) Neue spirotricyclische derivate und deren verwendung als phosphodiesterase-7-inhibitoren
DE60036803D1 (de) Arylmethyl-carbonylamino-thiazolderivate und ihre verwendung als antitumormittel
DE60131015D1 (de) Bakterielle gyrase-hemmer und deren verwendung
DE602004021037D1 (de) Phosphororganische indazolderivate und deren verwendung als proteinkinaseinhibitoren
ATE348805T1 (de) 2-acyl-indolderivate und deren verwendung als antitumormittel
DE60325761D1 (de) Diaminotriazole derivate und deren verwendung als protein kinase inhibitoren
ATE302193T1 (de) Benzoheterozyklen und ihre verwendung als mek inhibitoren
DE60023903D1 (de) Pyrimidin-2,4,6-trionen und deren verwendung als metalloproteinase inhibitoren
DE60112607T2 (de) 3-arylindolderivate und deren verwendung als cb2-rezeptoragonisten
ATE277910T1 (de) Urazil verbindungen und deren verwendung
DE60123210D1 (de) Picolinsäure-derivate und ihre verwendung als fungizide
DE59908600D1 (de) Substituierte benzimidazole und ihre verwendung als parp inhibitoren
DE60139477D1 (de) 2-cyanopyrrolidin-derivate und ihre verwendung als arzneimittel
ATE293620T1 (de) Indol-3-yl-derivate und deren verwendung als integrin-inhibitoren
DE60116894D1 (de) C-nitrosoanilinverbindungen und deren mischungen als polymerisationsinhibitoren
ATE418543T1 (de) Substituierte 1,4-dipiperidin-4-yl- piperazinderivate und deren verwendung als neurokininantagonisten
ATE329906T1 (de) Substituierte 2-anilino-benzimidazole und ihre verwendung als nhe-inhibitoren
DE60336266D1 (de) Substituierte 1-piperidin-4-yl-pyrrolidin-3-yl-piperazinderivate und deren verwendung als neurokinin antagonisten
DE50115716D1 (de) Tetrakisfluoroalkylborat-Salze und deren Verwendung als Leitsalze
ATE551329T1 (de) Chinazolinonderivate und deren verwendung als cb- agonisten
DE60037183D1 (de) Neue amidinbenzylamin-derivate und ihre verwendung als thrombin-inhibitoren

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee